MR contrast patterns predict therapy response
The permeability of gadolinium and the morphology of breast cancers can reliably predict whether those tumors will benefit from neoadjuvant chemotherapy, according to a study by researchers at Duke University.
The permeability of gadolinium and the morphology of breast cancers can reliably predict whether those tumors will benefit from neoadjuvant chemotherapy, according to a study by researchers at Duke University.
The vascularity of tumors and their reaction to blood-borne contrast predict a likely response to therapy. Tumors that were closely packed with cancer cells did not effectively retain contrast and were resistant to chemotherapy, said Oana Craciunescu, Ph.D., a Duke radiation oncologist, who reported the study results at the San Antonio Breast Cancer Symposium in December.
Tumors in which the blood vessels formed a ring pattern around the center were also resistant to chemotherapy because collapsed blood vessels in the center would not carry the drug there. The best responders were homogeneous tumors in which blood vessels were evenly distributed throughout the tumor.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
